HCW Biologics SVP buys 7,736 shares in placement
HCW Biologics Inc. SVP of Business Development Lee Flowers purchased 7,736 shares of common stock at $2.585 per share on July 29, 2026, increasing his direct holdings to 8,691 shares.
Rhea-AI Filing Summary
HCW Biologics Inc. SVP of Business Development Lee Flowers purchased 7,736 shares of common stock at $2.585 per share on July 29, 2026, increasing his direct holdings to 8,691 shares. The shares were bought directly from the issuer in a private placement under a Securities Purchase Agreement exempt from registration. Flowers is also entitled to receive common warrants exercisable for up to 7,736 additional shares, with issuance subject to stockholder approval under Nasdaq Listing Rule 5635(d); upon issuance, these warrants would be immediately exercisable and expire 5.5 years after issuance.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 7,736 shares
Net Buy
1 txn
Insider
Flowers Lee
Role
SVP of Business Development
Bought
7,736 shs ($20K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 7,736 | $2.585 | $20K |
Holdings After Transaction:
Common Stock — 8,691 shares (Direct)
Footnotes (1)
- F1. The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.
Key Figures
Shares purchased: 7,736 shares
Purchase price: $2.585 per share
Post-transaction holdings: 8,691 shares
+2 more
5 metrics
Shares purchased
7,736 shares
Common stock acquired by Lee Flowers on July 29, 2026
Purchase price
$2.585 per share
Price paid for HCW Biologics common stock in private placement
Post-transaction holdings
8,691 shares
Total common shares directly held by Lee Flowers after the purchase
Warrant entitlement
7,736 shares
Maximum common shares underlying warrants Flowers is entitled to receive
Warrant term
5.5 years
Warrants expire 5.5 years from their date of issuance
Key Terms
private placement, Securities Purchase Agreement, Nasdaq Listing Rule 5635(d), Rule 506(b) of Regulation D, +1 more
5 terms
private placement financial
"purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Nasdaq Listing Rule 5635(d) regulatory
"issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d)"
Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.
Rule 506(b) of Regulation D regulatory
"pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
Section 4(a)(2) regulatory
"exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HCW Biologics (HCWB) insider Lee Flowers purchase?
Lee Flowers purchased 7,736 shares of HCW Biologics common stock at $2.585 per share on July 29, 2026, buying directly from the issuer in a private placement under a Securities Purchase Agreement exempt from registration.
Was the HCW Biologics (HCWB) insider purchase an open-market transaction?
No. The 7,736-share acquisition by Lee Flowers was a private placement directly from HCW Biologics under a Securities Purchase Agreement dated July 29, 2026, rather than an open-market or brokerage trade.
What warrants is HCW Biologics (HCWB) insider Lee Flowers entitled to receive?
In addition to shares, Lee Flowers is entitled to common warrants exercisable for up to 7,736 shares of common stock. Issuance of these warrants requires stockholder approval and, once issued, they will be immediately exercisable and expire 5.5 years later.
Under what exemptions was the HCW Biologics (HCWB) private placement to Lee Flowers made?
The private placement to Lee Flowers is exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b) of Regulation D, as referenced in the Securities Purchase Agreement dated July 29, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
